Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Invest New Drugs. 2018 Aug 3;37(2):364–374. doi: 10.1007/s10637-018-0647-0

Table 1.

GI50 (nM) of Apra S10 and IC50 (nM) of a clinically approved receptor tyrosine kinase (EGFR) inhibitor on both established and new patient derived pancreatic cancer cell lines

Compounds Apra S10 (nM) erlotinib hydrochloride (nM)
EC68 0.35 8960
EC46 0.32 2410
PANC-1 2.75 13100